Guillermo O.
- Country
- Spain
- Department
- Hematology
Research Overview
- Phase I-Ib Study of the Safety and Immunobiology of Prophylactic Lymphocyte and Natural Killer Cell Infusion Following Allogeneic Hematopoietic Cell Transplantation to Prevent Graft-versus-Host Disease
- Phase 3 Randomized Open-Label Study of Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Steroid-Refractory Acute Graft-Versus-Host Disease
- Phase 2 Multicenter Study Evaluating Axatilimab Efficacy, Safety, and Tolerability in Recurrent/Refractory Chronic Graft Versus Host Disease
Data & Insights
Has run more than one trial at 70 of 132 partner sites.
Specializations
Transplant Immunology
The investigator specializes in studying immune responses following allogeneic hematopoietic cell transplantation, with particular emphasis on developing therapeutic strategies for managing transplant complications.
- Lymphocyte and NK cell therapy
- Immune reconstitution
- Cellular immunotherapy
Work includes investigation of prophylactic cellular infusions to improve transplant outcomes.
GVHD Management
Focused on advancing treatment options for graft-versus-host disease, particularly in its chronic form, through evaluation of novel therapeutic agents and combination approaches.
- Corticosteroid-based therapies
- Novel immunomodulatory agents
- Treatment optimization strategies
Explores innovative therapeutic combinations for moderate to severe GVHD manifestations.
Clinical Immunobiology
Investigates the immunobiological mechanisms underlying post-transplant complications and therapeutic interventions in the context of allogeneic cell therapy.
- Immune response monitoring
- Safety assessment protocols
- Therapeutic biomarker evaluation
Integrates immunobiological insights into clinical therapeutic strategies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.